| Autor: |
Zhou, Huan, Xie, Jing, Zhu, Xingyu, Li, Xiaoyi, Yu, Xiaohui, Zhang, Yong, Su, Yue, He, Cuixia, Zhu, Minhui, Li, Xiao li, Liu, Yuanyuan, Chen, Juan, Cheng, Dongmei, Chen, Mengmeng, Wang, Ying, Ge, Qin, Fan, Ling, Wang, Ying, Shao, ZhongHuan, Liu, Bingyan, Shan, Rongfang, Dai, Xiangrong, Wang, Hongju, Wang, Huaxue |
| Zdroj: |
Expert Opinion on Drug Metabolism & Toxicology; September 2021, Vol. 17 Issue: 9 p1149-1156, 8p |
| Abstrakt: |
ABSTRACTPurposeTo compare the pharmacokinetics, pharmacodynamics and safety of the new prolonged-release leuprorelin acetate microspheres for injection (3.75 mg) with the reference product Enantone® (3.75 mg).Method48 healthy male volunteers were enrolled and randomly received a single 3.75 mg dose of the test drug or Enantone®.ResultsThere were no significant differences in Cmax, AUC0-tand AUC0-48between the test group and reference group (P > 0.05). The 90% confidence intervals of the two groups were 87.49%~112.74%, 97.15%~154.25%, and 80.85%~109.01%, respectively. Twenty-eight days after administration, both groups reached 100.0% castration level; there was no difference in the time from administration to reaching castration level between the two groups (P > 0.05); However, the difference between the two groups in the duration of castration level was statistically significant (P < 0.05). There were no major or serious adverse events, and the severity was mild to moderate.ConclusionThe pharmacokinetic characteristics of leuprorelin in two groups were consistent. The two groups exhibited similar inhibitory effects on testosterone and more subjects in the test group maintained a longer castration time than those in the reference group. |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
